Bellvitge Biomedical Research Institute:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Bellvitge Biomedical Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9407)・商品コード:DATA904C9407
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:49
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center that offers health care development solutions. The center conducts clinical and basic research for developing treatments and techniques to improve health care. It offers its research work in the fields of neurosciences, infectious pathology and transplants, cancer and human molecular genetics, growth factors, inflammatory, chronic and degenerative diseases, hormones and diabetes, epigenetics and cancer biology. IDIBELL also conducts translational medicine research for aspects of neurosciences, biomedicine, mainly cancer, and other prevalent diseases. The center manages the research of oncology institutions, universities, and other healthcare facilities. IDIBELL is headquartered in Barcelona, Spain.

Bellvitge Biomedical Research Institute – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Oxford Immunotec Enters into Licensing Agreement with IDIBELL 11
Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 12
Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 13
Histocell Enters Into Licensing Agreement With IDIBELL For Acute Pulmonary Diseases Patent 14
Bellvitge Biomedical Research Institute – Key Competitors 15
Bellvitge Biomedical Research Institute – Key Employees 16
Bellvitge Biomedical Research Institute – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Legal and Regulatory 18
Mar 23, 2018: IDIBELL obtains the TECNIO certification as a public technology facilitator 18
Government and Public Interest 19
Sep 25, 2018: IDIBELL researchers receive AECC grants on World Cancer Research Day 19
Aug 11, 2018: A new epigenetic signature predicts the response to immunotherapy in lung cancer 21
Aug 01, 2018: The biochemical signature of the synapse in a model of Down syndrome is identified with high resolution 22
Jun 27, 2018: New combined treatment shows promise in Hepatocellular Carcinoma 23
Jun 11, 2018: New epigenetic drug against Mantle Cell Lymphoma 24
May 14, 2018: Scientists discover a variation of the genome predisposing to Alzheimer’s disease 25
Apr 20, 2018: The EPICUP Project receives a Pfizer Foundation Innovation award 26
Apr 05, 2018: A potential new therapeutic target for Ewing sarcoma 27
Mar 15, 2018: Creation of a web platform for the identification of fronto-subcortical connectivity alterations in brain disorders 28
Feb 20, 2018: RAC1 protein could be a new therapeutic target to fight neurodegeneration in Parkinson’s disease 29
Jan 31, 2018: EU empowers four IDIBELL researchers with Marie Sklodowska-Curie Individual Fellowships 31
Jan 04, 2018: IDIBELL-ICO researchers identify a new therapeutic target to fight metastasis in ovarian cancer 32
Jan 04, 2018: IDIBELL researchers – ICO identify a new therapeutic target to combat metastasis in ovarian cancer 33
Jan 02, 2018: Alex Vaquero is awarded 200,000 euros from Worldwide Cancer Research to better understand the origin of cancer 34
Dec 19, 2017: Mild obsessive-compulsive symptoms are associated with variations of cerebral anatomy in healthy children 35
Dec 18, 2017: European project EU-TRAIN to improve the results in kidney transplant receives more than six million euros 36
Nov 21, 2017: The isoforms of the HP1 protein differentially regulate the organization and structure of heterochromatin 37
Oct 09, 2017: A new genetic marker accounts for up to 1.4% of cases of hereditary colon cancer 38
Oct 03, 2017: IDIBELL scientists identify a key regulator of the acquisition of immune tolerance to tumor cells in cancer patients 39
Jan 31, 2017: European experts highlight the potential of xenografts in personalized oncology 40
Product News 41
Jun 07, 2018: First photoactive drug to fight Parkinson’s disease 41
May 09, 2018: A new drug shows preclinical efficacy in Rett syndrome 43
Apr 11, 2017: First photoactive drug for pain treatments 44
Jan 11, 2018: ICO-IDIBELL researchers successfully test a new combination therapy in sarcomas 46
Jan 11, 2018: IDIBELL researchers successfully test a new combination therapy in sarcomas 47
Other Significant Developments 48
Jun 22, 2018: CRISPR-editing of a single aminoacid make a whole animal more resistant to cisplatin-based chemotherapy 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Key Facts 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellvitge Biomedical Research Institute, Deals By Therapy Area, 2012 to YTD 2018 9
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxford Immunotec Enters into Licensing Agreement with IDIBELL 11
Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 12
Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 13
Histocell Enters Into Licensing Agreement With IDIBELL For Acute Pulmonary Diseases Patent 14
Bellvitge Biomedical Research Institute, Key Competitors 15
Bellvitge Biomedical Research Institute, Key Employees 16

List of Figures
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bellvitge Biomedical Research Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Bellvitge Biomedical Research Institute:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9407)販売に関する免責事項を必ずご確認ください。
★調査レポート[Bellvitge Biomedical Research Institute:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆